| Literature DB >> 33187527 |
Reuben Musarandega1, Joanna Robinson2, Priti Dave Sen2, Anna Hakobyan2, Angela Mushavi3, Agnes Mahomva3, Godfrey Woelk4.
Abstract
BACKGROUND: Achievement of the elimination target for mother-to-child transmission (MTCT) of HIV in selected countries has increased hope to end the HIV epidemic in children across the world. However, MTCT rates remain well above the 5% elimination target in most sub-Saharan Africa countries. These countries require innovative strategies to scale-up their interventions to end paediatric HIV. We describe how the Elizabeth Glaser Paediatric AIDS Foundation (EGPAF) consortium and the Children's Investment Fund Foundation (CIFF) used the critical path method to facilitate rapid expansion and optimization of 2010 and 2013 WHO PMTCT guidelines to reduce Zimbabwe's MTCT rate from 22% in 2010 to 6.4% in 2015.Entities:
Keywords: Critical path method; Elimination; PMTCT; Paediatric HIV; Quality improvement; Vertical transmission
Mesh:
Year: 2020 PMID: 33187527 PMCID: PMC7663875 DOI: 10.1186/s12913-020-05900-4
Source DB: PubMed Journal: BMC Health Serv Res ISSN: 1472-6963 Impact factor: 2.655
Fig. 1Zimbabwe MTCT rates, 2000–2015 [Source: MoHCC, HIV estimates report, 2016]. Final MTCT. MTCT at 6 weeks. Target < 5%
Interventions implemented from 2011 to 2015 to improve critical path indicators and time of introducing them
| Critical Path Indicator | Period when intervention was introduced | Intervention implemented | |
|---|---|---|---|
| Year | Quarter | ||
| ANC Bookings | 2011 | Q2 | Incorporated PMTCT messaging in VHW training materials, trained and engaged VHWs in community mobilization for PMTCT and conducted mass-media campaigns to promote early ANC bookings. |
| HIV Testing | 2011 | Q2 | Trained more nurses to offer rapid HIV testing to pregnant women; tracked availability of test kits at site level and helped to redistribute as necessary to avoid stock outs. |
| Maternal AZT Prophylaxis | 2011 | Q2 | Introduced integrated PMTCT curriculum which trained MNCH nurses to dispense AZT to HIV-positive pregnant women according to 2010 WHO guidelines. |
| CD4 Testing | 2011 | Q4 | Procured 154 POC CD4 testing machines and distributed to MNCH clinics and EDTA tubes for remote clinics to collect and send blood specimens for CD4 testing at sites with CD4 testing machines. |
| Mothers’ ART | 2011 | Q4 | Introduced ART in MNCH and trained MNCH nurses to initiate eligible HIV-positive pregnant women on ART rather than referring them to existing ART clinics for initiation by doctors. |
| Infant ARVs | 2011 | Q2 | Changed HIV-exposed infants’ ARV prophylaxis from seven days daily AZT dose to daily NVP dose until 7 days after breastfeeding. |
| EID | 2011 | Q2 | Incorporated EID training into PMTCT training materials and trained nurses in all MNCH facilities to offer EID services. |
| All indicators | 2011 | Q2 | Quarterly data analysis, review of site level performance, implementing PDSA cycles to improve the indicators |
PMTCT prevention of mother-to-child transmission, VHW Village health worker, ANC Antenatal care, MNCH Maternal, neonatal and child health, AZT Zidovudine, POC Point of care, EDTA Ethylenedia-minetetraacetic acid, ART Antiretroviral therapy, NVP Nevirapine, EID Early infant diagnosis, DBS Dried blood spot
Critical path logical framework
| Critical path impact goal | To reduce the MTCT rate from an estimated 30% in 2010 to less than 12 in 2015 |
|---|---|
| ↑ | |
| Critical path indicators (CPIs) | ➢ Number and % women booked for first ANC visit (ANC booking is attending at least one ANC visit and is counted at the 1st ANC visit) ➢ Number and % women tested for HIV in ANC ➢ Number and % HIV-positive women started on AZT prophylaxis in ANC ➢ Number and % pregnant women eligible for ART by CD4 count in ANC ➢ Number and % eligible pregnant women initiated on ART in ANC ➢ Number and % HIV-exposed infants started on Nevirapine prophylaxis ➢ Number and % infants (< 2 months age) tested for HIV using DNA PCR |
| ↑ | |
| Programme management indicators (PMIs) | ➢ Number of sites offering comprehensive PMTCT services (HIV testing and ARVs for PMTCT) ➢ Number of sites offering ART services on-site (in MNCH or ART clinic) ➢ Number of sites offering CD4 testing on-site (using point-of-care machine or on-site laboratory CD4 testing machine) ➢ Number of sites offering EID services on-site (collecting dried blood spot and sending to a central laboratory for testing) ➢ Number of health facility nurses trained on PMTCT, ART, EID etc. ➢ Number of sites with an interruption in HIV testing for at least one day (due to absence of trained rapid HIV testers or stock-out of HIV test kits) ➢ Number of sites with a stock-out of maternal and infant ARVs ➢ Number of sites visited for supportive supervision |
| ↑ | |
| Critical path activities | ➢ Supporting programme coordination, adaptation of global PMTCT guidelines, developing training materials, technical working groups etc. ➢ Supporting rapid roll-out of new PMTCT guidelines in health facilities ➢ Training and mentoring health facility nurses on PMTCT guidelines and use of PDSA cycles to improve PMTCT service delivery ➢ Providing and maintaining POC devices for CD4 testing in ANC ➢ Supporting EID and CD4 specimen courier services ➢ Supporting HIV test-kit and ARV stock management and redistribution |
Fig. 2Number of sites offering or with interruptions in PMTCT services related to critical path indicators, 2000–2015
Fig. 3Trends in quarterly critical path indicator results, 2010–2015. ANC bookings. HIV testing. AZT prophylaxis. CD4 testing. Mothers ART. Infant NVP. EID
Comparison of number and percentage of women and infants receiving PMTCT services, before (2006–2010) and during (2011–2015) the EGPAF-CIFF CPM project
| Indicator | Number of women and infants receiving PMTCT services (numerator) and percentage, out of those eligible (denominator) in pre-intervention and intervention period | % change in | Person’s Chi2 test | |
|---|---|---|---|---|
| Pre-Intervention Period | Intervention Period | |||
| Pregnant women booked for ANC | 59% (1,176,003/1,985,076) | 97% (2,048,283/2,105,205) | 74% | < 0.001 |
| Pregnant women tested for HIV in ANC | 80% (941,293/1,176,003) | 99% (1,953,814/1,972,936) | 108% | < 0.001 |
| HIV-positive pregnant women dispensed ARVS | 24% (34,330/141,064) | 74% (123,547/167,839) | 260% | < 0.001 |
| HIV-positive pregnant women CD4 tested | 11% (15,543/141,064) | 62% (123,578/197,788) | 695% | < 0.001 |
| HIV-positive pregnant women initiated ART | 2% (3287/141,064) | 42% (83,494/197,788) | 2440% | < 0.001 |
| HIV-exposed infants initiated ARV prophylaxis | 70% (98,898/141,064) | 85% (244,814/287,543) | 148% | < 0.001 |
| Infants HIV tested using DNA PCR < 2 months | 9% (12,494 /141,064) | 58% (167,291/287,543) | 1239% | < 0.001 |
aMeasures the change in the numbers provided PMTCT services between the pre-intervention and intervention period
Regression discontinuity results for critical path indicators; 2010–2015
| Indicator | Slope of linear curve before introducing intervention (β1) | Slope of linear curve after introducing intervention (β2) | Decision | |
|---|---|---|---|---|
| Slope (95% CI) | Slope (95% CI) | |||
| ANC Bookings | 0.3434 | 0.001 (−0.005–0.006) | 0.310 (0.220–0.401) | β2 > β1 > 0 |
| HIV Testing | 0.1542 | −0.001 (− 0.004–0.002) | 0.029 (− 0.023–0.812) | a |
| AZT Prophylaxis | 0.8391 | 0.142 (− 0.002–0.030) | 0.271 (0.108–0.443) | β2 > β1 > 0 |
| CD4 Testing | 0.0560 | 0.008 (0.001–0.015) | 0.168 (0.040–0.296) | β2 > β1 > 0 |
| Mothers’ ART | 0.0024 | 0.005 (−0.003–0.014) | 0.160 (0.036–0.282) | β2 > β1 > 0 |
| Infant ARVs | 0.3617 | 0.007 (0.002–0.012) | −0.064 (− 0.144–0.017) | a |
| EID | 0.1502 | 0.010 (− 0.002–0.022) | 0.309 (0.107–0.511) | β2 > β1 > 0 |
* Indicator meets normal distribution criteria if P > 0.05 or sample is large (> 3000 in all indicators, Table 3)
a 95% CI of β and β overlapping or β < β hence no difference in slope between the two segments of the indicator’s curve, before and after the start of interventions